Bio Path Holdings Stock Performance
| BPTH Stock | USD 0.06 0.01 21.43% |
The firm shows a Beta (market volatility) of 3.75, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio Path will likely underperform. At this point, Bio Path Holdings has a negative expected return of -0.47%. Please make sure to confirm Bio Path's variance, potential upside, as well as the relationship between the Potential Upside and day typical price , to decide if Bio Path Holdings performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bio Path Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Bio |
Bio Path Relative Risk vs. Return Landscape
If you would invest 10.00 in Bio Path Holdings on October 26, 2025 and sell it today you would lose (4.50) from holding Bio Path Holdings or give up 45.0% of portfolio value over 90 days. Bio Path Holdings is currently does not generate positive expected returns and assumes 10.0964% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of otc stocks are less volatile than Bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bio Path Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio Path's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Bio Path Holdings, and traders can use it to determine the average amount a Bio Path's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Bio Path is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio Path by adding Bio Path to a well-diversified portfolio.
Bio Path Fundamentals Growth
Bio OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Bio Path, and Bio Path fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio OTC Stock performance.
| Return On Equity | -11.6 | |||
| Return On Asset | -1.94 | |||
| Current Valuation | 531.06 K | |||
| Shares Outstanding | 5.77 M | |||
| Price To Earning | (6.21) X | |||
| Price To Book | 2.33 X | |||
| EBITDA | (15.76 M) | |||
| Cash And Equivalents | 17.02 M | |||
| Cash Per Share | 2.38 X | |||
| Total Debt | 113 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (11.54 M) | |||
| Earnings Per Share | (8.34) X | |||
| Total Asset | 3.22 M | |||
| Retained Earnings | (107.61 M) | |||
| Current Asset | 9.59 M | |||
| Current Liabilities | 937 K | |||
About Bio Path Performance
By evaluating Bio Path's fundamental ratios, stakeholders can gain valuable insights into Bio Path's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio Path has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio Path has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.Things to note about Bio Path Holdings performance evaluation
Checking the ongoing alerts about Bio Path for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Bio Path Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio Path Holdings generated a negative expected return over the last 90 days | |
| Bio Path Holdings has high historical volatility and very poor performance | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Bio Path's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio Path's stock is overvalued or undervalued compared to its peers.
- Examining Bio Path's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio Path's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio Path's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Bio Path's otc stock. These opinions can provide insight into Bio Path's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio OTC Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |